AstraZeneca Reports Q3 2026 Financial Results

AstraZeneca reported higher revenue and attributable profit in the third quarter of 2026, though it did not provide specific totals or growth rates. The company announced a $1.5 billion savings drive to support investment in its drug pipeline. Oncology remained a growth driver, with Imfinzi sales up 26% at constant currency. AstraZeneca reiterated its full-year guidance, citing positive Phase III trial results that strengthened its long-term pipeline outlook.